Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease.
Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant disease.
复制标题
DOI：
10.1182/blood.v58.4.759.759
复制
发表时间：
1981-10
期刊：
影响因子：
20.3
通讯作者：
J. Rowley;H. Golomb;J. Vardiman
中科院分区：
文献类型：
--
作者：
J. Rowley;H. Golomb;J. Vardiman
对26例原发性恶性肿瘤治疗后发生急性非淋巴细胞白血病（ANLL）或骨髓增生异常综合征的患者进行了细胞遗传学研究。15例患者接受放疗和化疗，7例仅接受化疗，4例仅接受放疗。这些治疗组从诊断初始疾病到发生骨髓功能障碍的中位时间分别为50、46和49个月。25例患者骨髓细胞核型异常。在25例非整倍体患者中，23例患者的5号和/或7号染色体部分或全部丢失。仅在既往患有恶性淋巴瘤的患者中观察到5号基因的缺失，而在这些患者以及患有其他恶性肿瘤的患者中观察到7号基因的缺失。两个编号的缩写。5和7发生在53%的患者与联合治疗，只有27%的患者与任何一种方式单独治疗。虽然这些变化明显不同于淋巴瘤，但它们与25%的ANLL新发非整倍体患者相似。
Cytogenetic studies were performed on 26 patients who developed acute nonlymphocytic leukemia (ANLL) or a dysmyelopoietic syndrome after treatment of a primary malignancy. Fifteen patients had radiotherapy and chemotherapy, seven had only chemotherapy, and four had only radiotherapy. The median times from diagnosis of the initial disease to the development of bone marrow dysfunction for these treatment groups were 50, 46, and 49 mo, respectively. Twenty-five patients had an abnormal karyotype in myeloid cells. Loss of part or all of no. 5 and/or no. 7 was noted in 23 of 25 patients with aneuploidy. Loss of no. 5 was noted only in patients who previously had malignant lymphoma, whereas loss of no. 7 was seen in these patients as well as in those who had other malignancies. Abnormalities of both nos. 5 and 7 occurred in 53% of the patients treated with combined therapy and in only 27% of patients treated with either modality alone. Although these changes are distinctly different from those noted in lymphomas, they are similar to those seen in 25% of aneuploid patients with ANLL de novo.